

CITATION REPORT

List of articles citing

Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection

DOI: 10.1523/jneurosci.3200-07.2008

Journal of Neuroscience, 2008, 28, 163-76.

Source: <https://exaly.com/paper-pdf/44539132/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
132	Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. 2008 , 7, 854-68		572
131	Epigenetics in the nervous system. <i>Journal of Neuroscience</i> , 2008 , 28, 11753-9	6.6	177
130	Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. <i>Journal of Neuroscience</i> , 2009 , 29, 2824-32	6.6	51
129	Role of histone acetylation in the activity-dependent regulation of sulfiredoxin and sestrin 2. 2009 , 4, 152-8		30
128	Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. 2009 , 40, 2899-905		95
127	Putting the HDAC back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. 2009 , 18, 573-84		64
126	HDAC6 is a target for protection and regeneration following injury in the nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 19599-604	11.5	242
125	Development of histone deacetylase inhibitors as therapeutics for neurological disease. 2009 , 4, 775-784		20
124	Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. 2009 , 4, 842-52		40
123	Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. 2009 , 4, 1095-105		37
122	Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups. 2009 , 4, 1292-301		7
121	Brain Poster Session: Experimental Cerebral Ischemia In vitro. 2009 , 29, S155-S165		
120	Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. 2009 , 111, 976-87		115
119	Creating zinc monkey wrenches in the treatment of epigenetic disorders. 2009 , 13, 263-71		16
118	Multiple roles of HDAC inhibition in neurodegenerative conditions. 2009 , 32, 591-601		483
117	Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. 2009 , 88, 170-83		116
116	Role of epigenetic regulatory mechanisms in neonatal hypoxic-ischemic brain injury. 2009 , 72, 692-3		5

115	DNA Methylation in Breast Cancer. 2009 , 151-175		
114	Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. 2010 , 69, 573-81	65	
113	LIM domain only 4 protein promotes granulocyte colony-stimulating factor-induced signaling in neurons. 2010 , 67, 949-57	14	
112	Protection by D609 through cell-cycle regulation after stroke. 2010 , 41, 206-17	13	
111	Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. 2010 , 1354, 172-8	72	
110	Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. 2010 , 115, 806-13	42	
109	Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. 2010 , 106, 272-84	93	
108	The Role of Histone Deacetylases in Neurodegenerative Diseases and Small-Molecule Inhibitors as a Potential Therapeutic Approach. 2010 , 1-56		
107	CXCL12 inhibits expression of the NMDA receptor NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival. 2010 , 1, e33	48	
106	HDAC inhibitors and neurodegeneration: at the edge between protection and damage. 2010 , 62, 11-7	99	
105	Histone deacetylase inhibition promotes Caspase-independent cell death of ventral midbrain neurons. 2011 , 48, 117-28	8	
104	Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. 2011 , 17, 448-56	59	
103	Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. 2011 , 17, 699-704	80	
102	A critical time window for the survival of neural progenitor cells by HDAC inhibitors in the hippocampus. 2011 , 31, 159-64	15	
101	Therapeutic application of histone deacetylase inhibitors for stroke. 2011 , 11, 138-49	18	
100	Epigenetic regulation of gene expression in physiological and pathological brain processes. 2011 , 91, 603-49	279	
99	Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. <i>Journal of Neuroscience</i> , 2011 , 31, 6858-70	6.6	96
98	Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. 2011 , 286, 4819-28		57

97	Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration. 2011 , 4, 1183-1195		18
96	Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity. <i>Journal of Neuroscience</i> , 2011 , 31, 3990-9	6.6	93
95	Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration. 2012 , 2012, 908724		10
94	Epigenetics and stroke risk – beyond the static DNA code. 2012 , 67		1
93	Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation. <i>Journal of Neuroscience</i> , 2012 , 32, 6561-9	6.6	47
92	Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection. 2012 , 39, 751-8		60
91	Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of β SMA KO Mouse Model of Spinal Muscular Atrophy. <i>ACS Chemical Neuroscience</i> , 2012 , 3, 5-11	5.7	27
90	Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and β -tetrahydrocannabinol in BV-2 microglial cells. 2012 , 165, 2512-28		62
89	Inhibition of p53 transactivation functionally interacts with microtubule stabilization to suppress excitotoxicity-induced axon degeneration. 2012 , 427, 100-6		3
88	Toll-like signaling and the cytokine IL-6 regulate histone deacetylase dependent neuronal survival. <i>PLoS ONE</i> , 2012 , 7, e41033	3.7	9
87	Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury. 2013 , 10, 798-807		35
86	Mitochondria and ALS: implications from novel genes and pathways. 2013 , 55, 44-9		70
85	Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. 2013 , 10, 789-97		62
84	Effects of sodium butyrate on oxidative stress and behavioral changes induced by administration of D-AMPH. <i>Neurochemistry International</i> , 2013 , 62, 425-32	4.4	21
83	Epigenetics and the modulation of neuroinflammation. 2013 , 10, 782-8		41
82	A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. <i>Neurobiology of Disease</i> , 2013 , 49, 13-21	7.5	22
81	Epigenetics and the environment: in search of the "toleroasome" vital to execution of ischemic preconditioning. 2013 , 4, 56-62		11
80	Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. <i>Neurobiology of Disease</i> , 2013 , 49, 177-89	7.5	71

79	Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. 2013 , 31, 370-81		54
78	A functional role of the cyclin-dependent kinase inhibitor 1 (p21(WAF1/CIP1)) for neuronal preconditioning. 2013 , 33, 351-5		8
77	Development and therapeutic implications of selective histone deacetylase 6 inhibitors. 2013 , 56, 6297-313		95
76	Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?. 2013 , 140, 34-52		152
75	Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block. 2013 , 33, 809-18		22
74	Epigenetic mechanisms in cerebral ischemia. 2013 , 33, 1335-46		75
73	Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. <i>Journal of Neuroscience</i> , 2013 , 33, 8621-32	6.6	74
72	Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. 2013 , 64, 81-96		75
71	Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition. <i>Journal of Neuroscience</i> , 2014 , 34, 14328-37	6.6	20
70	JAZ (Znf346), a SIRT1-interacting protein, protects neurons by stimulating p21 (WAF/CIP1) protein expression. 2014 , 289, 35409-20		12
69	Histone acetylation and arachidonic acid cytotoxicity in HepG2 cells overexpressing CYP2E1. 2014 , 387, 271-80		6
68	HSF1 protects neurons through a novel trimerization- and HSP-independent mechanism. <i>Journal of Neuroscience</i> , 2014 , 34, 1599-612	6.6	46
67	Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage. 2014 , 16, 727-41		21
66	MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury. 2014 , 129, 509-15		31
65	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. 2014 , 13, 673-91		1028
64	Dysregulated expression of lipid storage and membrane dynamics factors in Tia1 knockout mouse nervous tissue. 2014 , 15, 135-44		38
63	A selective phenelzine analogue inhibitor of histone demethylase LSD1. 2014 , 9, 1284-93		66
62	Effects of histone deacetylase inhibition on the survival, proliferation and migration of Schwann cells, as well as on the expression of neurotrophic factors and genes associated with myelination. 2014 , 34, 599-605		12

61	A transient ischemic environment induces reversible compaction of chromatin. 2015 , 16, 246		47
60	Histone Deacetylases Exert Class-Specific Roles in Conditioning the Brain and Heart Against Acute Ischemic Injury. <i>Frontiers in Neurology</i> , 2015 , 6, 145	4.1	23
59	Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology. 2015 , 89, 155-78		123
58	Anthelmintic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. 2015 , 22, 121-34		13
57	HDAC2 selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. <i>Journal of Neuroscience</i> , 2015 , 35, 1250-9	6.6	69
56	Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult. 2015 , 51, 1432-42		23
55	Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. 2015 , 291, 306-314		66
54	The relevance of epigenetics to occlusive cerebral and peripheral arterial disease. 2015 , 128, 537-58		13
53	Interplay between histone acetylation/deacetylation and poly(ADP-ribosyl)ation in the development of ischemic tolerance in vitro. 2015 , 92, 125-34		15
52	Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia. 2015 , 35, 1640-7		31
51	Innate and adaptive immune response in stroke: Focus on epigenetic regulation. 2015 , 289, 111-20		29
50	Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases. 2015 , 1628, 273-287		15
49	Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit. 2015 , 58, 6803-18		42
48	Integrative Mouse and Human Studies Implicate ANGPT1 and ZBTB7C as Susceptibility Genes to Ischemic Injury. 2015 , 46, 3514-22		12
47	Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery. 2015 , 268, 37-45		67
46	Epigenetic Regulation of Oxidative Stress in Ischemic Stroke. 2016 , 7, 295-306		75
45	Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?. 2016 , 625, 56-63		298
44	The effects of proteasomal inhibition on synaptic proteostasis. <i>EMBO Journal</i> , 2016 , 35, 2238-2262	13	34

43	Histone H3 acetylation in the postmortem Parkinson disease primary motor cortex. 2016 , 627, 121-5		25
42	A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. 2016 , 36, 426-41		23
41	Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells. 2016 , 625, 11-5		20
40	A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson disease. 2016 , 37, 103-116		30
39	Glutamate and ATP at the Interface Between Signaling and Metabolism in Astroglia: Examples from Pathology. 2017 , 42, 19-34		24
38	Reduced Expression of Foxp1 as a Contributing Factor in Huntington Disease. <i>Journal of Neuroscience</i> , 2017 , 37, 6575-6587	6.6	9
37	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer Disease Mice. 2017 , 42, 524-539		65
36	HDAC Inhibitor Sodium Butyrate-Mediated Epigenetic Regulation Enhances Neuroprotective Function of Microglia During Ischemic Stroke. 2017 , 54, 6391-6411		95
35	Gene expression in retinal ischemic post-conditioning. 2018 , 256, 935-949		7
34	Complex neuroprotective and neurotoxic effects of histone deacetylases. 2018 , 145, 96-110		38
33	Valproate and sodium butyrate attenuate manganese-decreased locomotor activity and astrocytic glutamate transporters expression in mice. 2018 , 64, 230-239		25
32	Therapeutic opportunities and pitfalls in the treatment of axon degeneration. <i>Current Opinion in Neurology</i> , 2018 , 31, 693-701	7.1	16
31	Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	20
30	Small Molecules: Therapeutic Application in Neuropsychiatric and Neurodegenerative Disorders. <i>Molecules</i> , 2018 , 23,	4.8	11
29	Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody library. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E7023-E7032	11.5	19
28	Senescence-associated β galactosidase activity in the developing avian retina. <i>Developmental Dynamics</i> , 2019 , 248, 850-865	2.9	9
27	Catalytic-independent neuroprotection by SIRT1 is mediated through interaction with HDAC1. <i>PLoS ONE</i> , 2019 , 14, e0215208	3.7	2
26	Unanchored tri-NEDD8 inhibits PARP-1 to protect from oxidative stress-induced cell death. <i>EMBO Journal</i> , 2019 , 38,	13	26

25	Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1679-1695	5.7	32
24	Epigenetic mechanisms of neurodegenerative diseases and acute brain injury. <i>Neurochemistry International</i> , 2020 , 133, 104642	4.4	16
23	Changes in Class I and IIb HDACs by μ Opioid in Chronic Rat Glaucoma Model. 2020 , 61, 4		3
22	Fatty acid metabolism in the progression and resolution of CNS disorders. <i>Advanced Drug Delivery Reviews</i> , 2020 , 159, 198-213	18.5	30
21	Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders. <i>Life Sciences</i> , 2020 , 243, 117278	6.8	27
20	The Chemical Biology of Ferroptosis in the Central Nervous System. <i>Cell Chemical Biology</i> , 2020 , 27, 479-498	8.98	52
19	Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases. <i>Neurobiology of Disease</i> , 2021 , 147, 105145	7.5	4
18	Exercise Factors Released by the Liver, Muscle, and Bones Have Promising Therapeutic Potential for Stroke. <i>Frontiers in Neurology</i> , 2021 , 12, 600365	4.1	1
17	The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research. <i>Frontiers in Cellular Neuroscience</i> , 2021 , 15, 698172	6.1	6
16	Rb deficiency induces p21cip1 expression and delays retinal degeneration in rd1 mice. <i>Experimental Eye Research</i> , 2021 , 210, 108701	3.7	0
15	HDAC2/3 inhibitor MI192 mitigates oligodendrocyte loss and reduces microglial activation upon injury: A potential role of epigenetics. <i>Open Veterinary Journal</i> , 2021 , 11, 447-457	1	
14	Oposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. <i>PLoS ONE</i> , 2008 , 3, e4090	3.7	142
13	In cortical neurons HDAC3 activity suppresses RD4-dependent SMRT export. <i>PLoS ONE</i> , 2011 , 6, e21056	3.7	11
12	β Tubulin Acetyltransferase Is a Novel Target Mediating Neurite Growth Inhibitory Effects of Chondroitin Sulfate Proteoglycans and Myelin-Associated Glycoprotein. <i>ENeuro</i> , 2018 , 5,	3.9	12
11	Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors. <i>ENeuro</i> , 2019 , 6,	3.9	40
10	Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5105-20	3.3	57
9	Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models. <i>Current Neuropharmacology</i> , 2017 , 15, 815-830	7.6	22
8	Epigenetic approaches to psychiatric disorders. <i>Dialogues in Clinical Neuroscience</i> , 2010 , 12, 25-35	5.7	74

7	Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke. <i>Biomedicines</i> , 2021 , 9,	4.8	1
6	Novel Multitarget Hydroxamic Acids with a Natural Origin CAP Group against Alzheimer's Disease: Synthesis, Docking and Biological Evaluation. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
5	Histone deacetylases as targets for the treatment of human neurodegenerative diseases. <i>Drug News and Perspectives</i> , 2009 , 22, 513-24		24
4	Cell Cycle Proteins as Key Regulators of Postmitotic Cell Death. <i>Yale Journal of Biology and Medicine</i> , 2019 , 92, 641-650	2.4	6
3	Histone deacetylases as targets for the treatment of human neurodegenerative diseases. 2009 , 22, 513		24
2	TGF- β is a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications. <i>Biomedicines</i> , 2022 , 10, 1206	4.8	0
1	Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells. 2023 , 24, 4720		1